“Based on the public data on IMMU-132 and available information regarding the Company’s pipeline, I believe the antibody-drug conjugates of Immunomedics have a high likelihood of improving the lives of countless patients with significant unmet medical needs…While the U.S. and global approval and commercialization of IMMU-132 for metastatic triple negative breast cancer are a key goal for me and my team, we simultaneously will be focused on developing IMMU-132 in multiple solid tumor indications, thereby laying the foundation to transform Immunomedics into a recognized leader in the field of antibody-drug conjugates.” – Michael Pehl, President and CEO of Immunomedics

Source: tnbctrial.com

IIMMU actual stock performance since I Know First’s bullish forecast.

Immunomedics, Inc., (NASDAQ:IMMU) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ most advanced product candidate is IMMU-132 (sacituzumab govitecan), an antibody-drug conjugate that has received Breakthrough Therapy Designation from the FDA for the treatment of patients with metastatic triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics’ immediate priority is to commercialize its most advanced product candidate, sacituzumab govitecan (IMMU-132), beginning in the U.S., with metastatic triple-negative breast cancer as the first indication, thus becoming a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. After it announced its quarterly report on May 9^th, the stock enjoyed another surge to $24.16, with a price increase of 28.03% by June 8^th. The stock is still up-trending.

Analyst growth expectation. Source: Simplywall.st

Total revenues were $0.5 million for the third fiscal quarter ended March 31, 2018 and $1.8 million for the nine months ended March 31, 2018, compared to $1.3 million in the third fiscal quarter ended March 31, 2017 and $2.4 million for the nine months ended March 31, 2017. The decreases were due primarily to lower sales volume of LeukoScan® in Europe, so the company could put its primary focus on ADC business. Total costs and expenses in the third quarter and nine months of fiscal 2018 reached to $38.1 million and $90.4 million respectively due primarily to increases in research and development expenses as well as in sales and marketing expenses. However, in the future, analysts tend to have very bullish prospect on the company’s growth. According to Simply Wall St data, Immunomeics is expected to achieve a revenue growth of 80.2% per year, far exceeding the average level of 16% for biotech companies, and the expected earnings growth could reached to 56.4%, also well above the industry average of 23.4%.

At the short-term liabilities level of US$93.62 million liabilities, it appears that the company has been able to meet these commitments. As of March 31, 2018, the Company had $358.8 million in cash, cash equivalents, and marketable securities which it believes is sufficient to support its next phase of growth and continue operations into 2020. In March 2018, the Phase 3 ASCENT study dosed the first patient in Europe, reflecting the encouraging progress of the confirmatory trial with sacituzumab govitecan in patients with mTNBC. The Company will require additional funding in 2020 to complete its clinical trials currently underway or planned, to continue research and new development programs, to expand commercial applications for sacituzumab govitecan into earlier lines of therapy for mTNBC patients and for patients with other types of cancer indications, such as advanced urothelial cancer and other indications with high, unmet medical need, as a mono and combination therapy, and to continue operations.

Analysts recommendations

Source: Yahoo Finance

Currently, analysts from Yahoo Finance monitoring this stock tend to have the consensus that they would give very bullish forecast on the stock performance. All of three recommendations that analysts have given are buy or hold.

I Know First’s Algorithm Forecast performance for IMMU

On June 6th, 2017, I Know First Algorithm gave very bullish forecast on IMMU, which ranked as the top performing prediction with a return of 210.71%. The predictabilities also showed strong confidence that IMMU stock price was very likely to soar, with one-year predictability of 0.66, which was in accordance the actual stock performance. IMMU has risen 197.54% in the forecasting time period.

Go here to read how to interpret this diagram.

Current I Know First subscribers received this NVDA forecast on June 6th, 2017. To subscribe today, click here.